Partially Hydrolyzed Guar Gum (PHGG) for Amelioration of Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Microbial ColonizationRespiratory Tract DiseaseCOPD
- Interventions
- Dietary Supplement: Partially Hydrolyzed Guar Gum (PHGG)
- Registration Number
- NCT05126654
- Lead Sponsor
- Fu Jen Catholic University Hospital
- Brief Summary
Some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. An intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii.
The investigators designed a randomized control study, which enroll adults diagnosed with COPD. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated.
- Detailed Description
It is well known that some components of the diet could promote the growth of certain bacterial strains present in the intestine, which are closely associated with benefits for host health. In the previous study, the investigators found that an intestinal commensal Parabacteroides goldsteinii (Pg) was highlighted to be significantly negatively associated with severity of COPD. Furthermore, the investigators identify the potential prebiotics (PHGG) which may enrich the abundance of P. goldsteinii and increase the probiotic effect of P. goldsteinii. However, the effect of PHGG supplement on compositional and functional properties of the human microbiota with COPD still remains unclear.
In this proposal, the investigators designed a randomized control study, which enroll adults diagnosed with COPD. The investigators will review their past medical records and related image and lung function test. Then the two groups will receive PHGG or not. Stool samples will be collected. The ameliorative efficacy will be evaluated by questionnaire and lung function test. Intestinal microbiota and metabolome will be analyzed and the correlation with lung function indices will be further investigated. In the future, it may be used to investigate and analyze the change of microbiota and metabolome, then develop possible treatment options of COPD.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
- age of 40-85 years
- diagnosis of COPD made by pulmonologist
- provision of written informed consent
- severe and unstable comorbidities or active malignancy
- COPD exacerbation within the 4 weeks prior
- cognitive impairment or a psychiatric disorder
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description COPD with PHGG Partially Hydrolyzed Guar Gum (PHGG) COPD patient PHGG 5g/day for 1 month Healthy with PHGG Partially Hydrolyzed Guar Gum (PHGG) Healthy PHGG 5g/day for 1 month
- Primary Outcome Measures
Name Time Method FEV1 after PHGG 5 gram/day for 1 month change of FEV1
St. George's Respiratory Questionnaire (SGRQ) after PHGG 5 gram/day for 1 month change of SGRQ score, 0 the best, 100 the worst
FEV1/FVC% after PHGG 5 gram/day for 1 month change of FEV1/FVC%
MMEF% after PHGG 5 gram/day for 1 month change of MMEF%
Microbiota of stool after PHGG 5 gram/day for 1 month change of stool microbiota contribution
PEF after PHGG 5 gram/day for 1 month change of PEF
FEV3/FVC% after PHGG 5 gram/day for 1 month change of FEV3/FVC%
Modified Medical Research Council Dyspnea Scale (mMRC) after PHGG 5 gram/day for 1 month change of mMRC scale, 0 the best, 4 the worst
COPD Assessment Test (CAT) after PHGG 5 gram/day for 1 month change of CAT (0 the best, 40 the worst)
FEV1% after PHGG 5 gram/day for 1 month change of FEV1%
FVC after PHGG 5 gram/day for 1 month change of FVC
FVC% after PHGG 5 gram/day for 1 month change of FVC%
FEV3 after PHGG 5 gram/day for 1 month change of FEV3
FEV3% after PHGG 5 gram/day for 1 month change of FEV3%
MMEF after PHGG 5 gram/day for 1 month change of MMEF
PEF% after PHGG 5 gram/day for 1 month change of PEF%
blood cytokine after PHGG 5 gram/day for 1 month change of blood cytokine
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Yen-Liang Kuo
🇨🇳New Taipei City, Taiwan